TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03668444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXS- Supportive Text Group
Description: TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU- Treatment As Usual
Description: Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
Study: NCT00086138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Zoloft)
Description: Sertraline: range of 25 to 125 mg per day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo designed to mimic sertraline taken daily for 24 weeks
Study: NCT01760174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine bolus in transversus abdominis plane catheter
Description: Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain-infusion in epidural catheter
Description: Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours
Study: NCT02915705

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: burosumab
Description: solution for subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for subcutaneous (SC) injection
Study: NCT03422874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
Study: NCT03007927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Dexamethasone
Description: Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- physiological solution
Description: Bupivacaine 1,5 mg/kg- physiological solution
Study: NCT00281983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study: NCT01587664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NewBreez ILP
Description: NewBreez ILP implantation
Study: NCT04551170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: oral theophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule or elixir
Study: NCT03878810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: A video game-based physical activity training applied using a commercial game console.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: A video game-based physical activity training applied using a commercial game console.
Study: NCT01744028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
Study: NCT00105638

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program, by telephone
Study: NCT03699943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CaverStem

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CaverStem

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CaverStem
Study: NCT02166008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repamipide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02047019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Candesartan Cilexetil, 16 mg, capsule, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan matching placebo
Description: Candesartan matching placebo, capsule, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan matching placebo
Description: Candesartan matching placebo, capsule, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
Study: NCT03291574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
Study: NCT03150056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as a concomitant medication in combination with abiraterone
Study: NCT01201629

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: t DC stimulation
Description: tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t DC stimulation
Description: tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCStimulation
Description: 1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCStimulation
Description: 1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
Study: NCT03104634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate dihydrate
Description: Cross-over design with washout interval. Randomized order of active and placebo arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and delivery device matched to active intervention
Study: NCT02952924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered as per schedule described in individual arm.
Study: NCT00281983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT03298126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TR BAND removal protocol
Description: To assess radial artery patency after specific protocol used as already described in previous section.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TR BAND removal protocol
Description: To assess radial artery patency after specific protocol used as already described in previous section.
Study: NCT03095040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 combined with everolimus
Description: CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
Study: NCT00921492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency electro-acupuncture (EA)
Description: 2 Hz EA during 30 minutes, twice a week, 14 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meeting a therapist - attention control
Description: Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
Study: NCT02158299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avitene
Study: NCT02915705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Phosphate Supplement
Description: oral tablet; oral solution; oral powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active vitamin D
Description: tablet, oral solution
Study: NCT02158299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapylin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: axillary drainage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: axillary drainage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: axillary drainage
Study: NCT04044040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom screening with Targeted Early Palliative care (STEP)
Description: The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
Study: NCT02158299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reexamine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reexamine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reexamine
Study: NCT04021953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: People Like Us Online Video Series Intervention
Description: People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Health Pamphlet (Standard of Care)
Description: The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
Study: NCT00281983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT04021953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Pamphlet (Standard of Care)
Description: The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
Study: NCT01581281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
Study: NCT01964170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: subcutaneous
Study: NCT01819233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral dietary intervention
Description: Receive caloric restricted dietary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic conventional surgery
Description: Undergo definitive lumpectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Description: Receive dietary counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study: NCT02982681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive Glass
Description: The control site were packed with the bioactive glass graft alone
Study: NCT02283684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight laser PVP
Description: Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar TUVP
Description: Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
Study: NCT03690843

Intervention type: OTHER
Intervention: Test Battery
Description: All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.

Intervention type: OTHER
Intervention: Test Battery
Description: All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
Study: NCT02840539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
Description: Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles
Study: NCT02838797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RQ-00000010
Description: orally administered serotonin 4 receptor partial agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral acetate buffer
Study: NCT04152837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study: NCT03917446

Intervention type: DRUG
Intervention: Propofol bolus
Description: Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.

Intervention type: DRUG
Intervention: Propofol bolus
Description: Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.